Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Prognostic Significance of Protocadherin-10 (PCDH10) Promoter Methylation in Bladder Cancer

1 Dec 2012

Abstract excerpt

OBJECTIVE: To investigate the clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in serum-derived DNA from patients with bladder cancer. METHODS: PCDH10 promoter methylation status was determined using methylation-specific polymerase chain reaction of DNA extracted from serum of patients with bladder cancer, and age- and sex-matched controls. Clinical and pathological details...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23321168
DOI: 10.1177/030006051204000609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Prognostic Significance of Protocadherin-10 (PCDH10) Promoter Methylation in Bladder CancerPMID 23321168Read ↗

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancerSemantic proximity Read ↗

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancerSemantic proximity Read ↗

Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancerSemantic proximity Read ↗

Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine SedimentsSemantic proximity Read ↗

Clinical Significance of CDH13 Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell CarcinomaSemantic proximity Read ↗

The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published EvidenceSemantic proximity Read ↗

High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor MarkersSemantic proximity Read ↗

Urine cell-based DNA methylation classifier for monitoring bladder cancerSemantic proximity Read ↗

DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clinical Significance of the Methylated Cytosine-Phosphate-Guanine Sites of Protocadherin-10 Promoter for Evaluating the Prognosis of Gastric CancerSemantic proximity Read ↗

DNA Methylation Array Analysis Identifies Profiles of Blood-Derived DNA Methylation Associated With Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.